A New Therapeutic Vaccine Against Prostate Cancer.
A newly approved remedial prostate cancer vaccine won the abide Wednesday of a Medicare admonitory committee, increasing the chances that Medicare will pay for the drug. Officials from Medicare, the federal guarantee program for the elderly and disabled, will consider the committee's vote when making a final decision on payment. Such a conclusion is expected in several months, the Wall Street Journal reported vimax. The vaccine, called Provenge and made by the Dendreon Corp, costs $93000 per dogged and extends survival by about four months on average, according to results from clinical trials.
A muse about published in July in the New England Journal of Medicine found that the vaccine extended the lives of men with metastatic tumors unsubmissive to support hormonal treatment, compared with no treatment stomach. And the therapy involved less toxicity than chemotherapy.
Provenge is a curative (not preventive) vaccine made from the patient's own white blood cells. Once removed from the patient, the cells are treated with the stupefy and placed back into the patient. These treated cells then trigger an unaffected response that in turn kills cancer cells, leaving sane cells unharmed.
The vaccine is given intravenously in a three-dose schedule delivered in two-week intervals. "The game of trying to harness the immune system to fight cancer has been something that ladies and gentlemen have tried to attain for many years; this is one such strategy," study lead researcher Dr Philip Kantoff, a professor of nostrum at Harvard Medical School and a medical oncologist at the Dana-Farber Cancer Institute in Boston, told HealthDay.
Showing posts with label provenge. Show all posts
Showing posts with label provenge. Show all posts
Friday, April 22, 2016
Saturday, November 23, 2013
An Approved Vaccine To Treat Prostate Cancer Has Few Side Effects
An Approved Vaccine To Treat Prostate Cancer Has Few Side Effects.
The newly approved therapeutical prostate cancer vaccine, Provenge, is safe-deposit and has few team effects, a new study finds. In April, the US Food and Drug Administration approved the vaccine for use in men with advanced prostate cancer who had failed hormone therapy medworldplus. "Provenge was approved based on both security and clinical data," said edge researcher Dr Simon J Hall, seat of urology at Mount Sinai Medical Center in New York City.
This aegis data shows that there are very limited side effects, Hall added. The utility of the vaccine for patients with metastatic hormone-resistant prostate cancer is that it has fewer airs effects than chemotherapy, which is the only other treatment option for these patients, Hall explained click. In addition, Provenge has improved survival over chemotherapy, he added.
The typical survival time for men given Provenge is 4,5 months, although some patients axiom their lives extended by two to three years. "This is a newly to hand treatment, with very limited side effects, compared to anything else that a man would be insomuch as in this state," Hall said. Hall was to present the results on Monday at the American Urological Association annual assembly in San Francisco.
Data from four phase 3 trials, which included 904 men randomized to either Provenge or placebo, showed the vaccine extended survival, improved importance of sprightliness and had only mild side effects. In fact, more than 83 percent of the men who received Provenge were able to do discharge activities without any restrictions, the researchers noted.
The newly approved therapeutical prostate cancer vaccine, Provenge, is safe-deposit and has few team effects, a new study finds. In April, the US Food and Drug Administration approved the vaccine for use in men with advanced prostate cancer who had failed hormone therapy medworldplus. "Provenge was approved based on both security and clinical data," said edge researcher Dr Simon J Hall, seat of urology at Mount Sinai Medical Center in New York City.
This aegis data shows that there are very limited side effects, Hall added. The utility of the vaccine for patients with metastatic hormone-resistant prostate cancer is that it has fewer airs effects than chemotherapy, which is the only other treatment option for these patients, Hall explained click. In addition, Provenge has improved survival over chemotherapy, he added.
The typical survival time for men given Provenge is 4,5 months, although some patients axiom their lives extended by two to three years. "This is a newly to hand treatment, with very limited side effects, compared to anything else that a man would be insomuch as in this state," Hall said. Hall was to present the results on Monday at the American Urological Association annual assembly in San Francisco.
Data from four phase 3 trials, which included 904 men randomized to either Provenge or placebo, showed the vaccine extended survival, improved importance of sprightliness and had only mild side effects. In fact, more than 83 percent of the men who received Provenge were able to do discharge activities without any restrictions, the researchers noted.
Subscribe to:
Posts (Atom)